Finance

Lists
ANVS:NYSE
Annovis Bio Inc
USD 1,06
-0,47%
(-0,0050) 1D
14 Okt., 11:08:37 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANVS...
Open
USD 1,05
High
USD 1,08
Low
USD 1,01
Mkt. cap
45,03 m
Avg. vol.
1,20 m
Volume
244,27 k
52-wk high
USD 5,50
52-wk low
USD 1,01
EPS
-USD 1,78
Beta
1,23
Shares outstanding
42,68 m
No. of employees
8
Open
USD 1,05
High
USD 1,08
Low
USD 1,01
Mkt. cap
45,03 m
Avg. vol.
1,20 m
Volume
244,27 k
52-wk high
USD 5,50
52-wk low
USD 1,01
EPS
-USD 1,78
Beta
1,23
Shares outstanding
42,68 m
No. of employees
8
News stories
From web sources and news partners
About Annovis Bio Inc
CEOMaria-luisa Maccecchini
Employees8
Founded2008
HeadquartersMalvern, Pennsilvanië, Verenigde State van Amerika
Sector-
Websiteannovisbio.com
Analyst ratings
Based on 3 analysts giving stock ratings to ANVS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ANVS in the last 3 months.
Highest
Current USD 1,06
USD 17,00 (+1 511,37%)
Average
USD 10,67 (+911,37%)
Lowest
USD 7,00 (+563,51%)
Analyst
Recommendation
Action
Price target
Projected
Date
Boobalan Pachaiyappan
Roth MKM
Buy
Maintained
USD 7,00
+563,5%
09/04/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
USD 17,00
+1 511,4%
08/18/2026
Jason McCarthy
Maxim Group
Buy
Maintained
USD 8,00
+658,3%
08/17/2026
Unknown Analyst
Roth MKM
Buy
Initiated
USD 8,00
+658,3%
07/07/2026
Last report
14 Aug. 2026
Fiscal period
Q2 2026
-USD 0,40 / -USD 0,46
+13,04%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
6,29 m
8,75 m
16,72 m
12,01 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,14 m
955,15 k
1,19 m
2,37 m
Operating expense
7,43 m
9,71 m
17,91 m
14,38 m
Total operating expenses
7,43 m
9,71 m
17,91 m
14,38 m
Operating income
-7,43 m
-9,71 m
-17,91 m
-14,38 m
Other non operating income
20,00 k
-296,00 k
268,00 k
-603,34 k
EBT including unusual items
-7,26 m
-9,83 m
-17,61 m
-14,82 m
EBT excluding unusual items
-7,26 m
-9,83 m
-17,51 m
-14,82 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7,26 m
-9,83 m
-17,61 m
-14,82 m
Net profit margin
-
-
-
-
Earnings per share
-0,37
-0,39
-0,63
-0,40
Interest and investment income
152,32 k
167,74 k
137,80 k
160,23 k
Interest expense
-
-
-
-
Net interest expenses
152,32 k
167,74 k
137,80 k
160,23 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme